FMP
Neoleukin Therapeutics, Inc.
NLTX
NASDAQ
Inactive Equity
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
3.49 USD
0.05 (1.43%)
About
ceo
Ms. Donna M. Cochener-Metcalfe J.D.
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.neoleukin.comexchange
NASDAQ
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
CIK
0001404644
ISIN
US64049K2033
CUSIP
64049K104
Address
188 East Blaine Street
Phone
855 226 6447
Country
US
Employee
7
IPO Date
Mar 7, 2014
Key Executives
